Drug Safety

Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?
pp. 183-189(7)
Author: Bannwarth, Bernard

Extrapyramidal Symptoms with Atypical Antipsychotics: Incidence, Prevention and Management
pp. 191-208(18)
Author: Pierre, Joseph M.

Protease Inhibitor-Induced Diabetic Complications: Incidence, Management and Prevention
pp. 209-226(18)
Authors: Lien, Lillian F.; Feinglos, Mark N.

Tolerability of Paracetamol
pp. 227-240(14)
Authors: Graham, Garry G.; Scott, Kieran F.; Day, Richard O.

Tibolone and Endometrial Cancer: A Cohort and Nested Case-Control Study in the UK
pp. 241-249(9)
Authors: de Vries, Corinne S.; Bromley, Susan E.; Thomas, Hilary; Farmer, Richard D.T.

Identification of Priorities for Medication Safety in Neonatal Intensive Care
pp. 251-261(11)
Authors: Kunac, Desireé L.; Reith, David M.

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy
pp. 263-275(13)
Authors: Bravo, Alexandra E. Rätz; Tchambaz, Lydia; Krähenbühl-Melcher, Anita; Hess, Lorenzo; Schlienger, Raymond G.; Krähenbühl, Stephan